Members

Breast cancer is one of the most present forms of cancer for women’s worldwide. As is now, the current procedures and techniques to perform a needle biopsy are conducted by humans. As widely known, humans have human error. We, Machnet Medical Robotics bring the first semi real time MRI guided biopsy robot to the market. Robotizing human actions not only eliminates human error, but a single intervention procedure is created and therefore resulting in higher patient comfort and financial benefit. With our robot, this intervention is an MRI guided intervention, merging the best possible imaging technique with first time accuracy. With this being said, we are at the start of a whole new chapter where our robot can provide a platform for many other semi real time interventions. We, as Machnet Medical Robotics believe that this robot is the future in biopsy systems.

MimeCure is active in the development of innovative regenerative drugs against pulmonary diseases, such as COPD, asthma and pulmonary fibrosis. The company has proprietary compounds based on Osteoglycin. Current activities are merely focused around MimeCure’s lead compound MC002.

Obseq is a start-up developing an innovative healthcare service to support and improve treatment adherence among Dutch patients through digital, patient-centered care and guidance. The name of the service is Balto.

ParaMedir is a start-up that uses its two core technologies, microfluidics and biosensors to develop (bio)monitoring tools for continuous monitoring. The company was founded in Groningen in 2018 and it has been growing ever since. Currently, ParaMedir is applying its technology on the development of a medical device for the assessment of kidney function of AKI in IC settings, the UriMoni™. The UriMoni, allows continuous monitoring of key biomarkers for the assessment of kidney function, continuously and in real-time, via the integration of a series of (bio)sensors in a microfluidic device. In addition, the company is developing new biosensors, based on their proprietary technology for (continuous) monitoring of key biomarkers such as glucose, lactate, creatinine and urea in biologically relevant matrices for biomedical applications. ParaMedir also provides contract research services in the fields of microfluidics, biosensoring and biomonitoring/bioanalysis.